Skip to main content

Monahan Joseph's Form 4 filing

Aclaris Therapeutics, Inc. (ACRS) · filed Mar 3, 2023

Accession no.
0001209191-23-016065
Filed
Mar 3, 2023
Trade date
Mar 1-3, 2023
Filing delay
2 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 6 non-derivative transactions and 4 derivative transactions. Open-market sales total $385.6K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Monahan JosephCIK 0001861790Officer (Chief Scientific Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Mar 1, 2023Common StockMOption exerciseAcquired+13,750––105,136Direct
Mar 1, 2023Common StockMOption exerciseAcquired+50,000––155,136Direct
Mar 1, 2023Common StockMOption exerciseAcquired+10,925––166,061Direct
Mar 2, 2023Common StockSSaleDisposed−14,800$12.37−$183,076151,261Direct
Mar 2, 2023Common StockMOption exerciseAcquired+12,500––163,761Direct
Mar 3, 2023Common StockSSaleDisposed−16,037$12.63−$202,547.31147,724Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Mar 1, 2023Common StockMOption exerciseDisposed−13,750$0.00$00Direct
Mar 1, 2023Common StockMOption exerciseDisposed−50,000$0.00$0100,000Direct
Mar 1, 2023Common StockMOption exerciseDisposed−10,925$0.00$032,775Direct
Mar 2, 2023Common StockMOption exerciseDisposed−12,500$0.00$012,500Direct

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)